GOCO

goco-20251113FALSE000180822000018082202025-11-132025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 13, 2025

GoHealth, Inc. (Exact name of registrant as specified in its charter)

Delaware001-3939085-0563805 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

222 W Merchandise Mart Plaza, Suite 175060654 Chicago,Illinois (Address of principal executive offices)(Zip Code)

(312) 386-8200 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock, $0.0001 par value per shareGOCOThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, the Company issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are included herewith:

Exhibit NumberDescription 99.1Press Release issued by GoHealth, Inc. on November 13, 2025.

104Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GOHEALTH, INC.

Date:November 13, 2025By:/s/ Brendan Shanahan Brendan Shanahan Chief Financial Officer (Principal Financial Officer)

goco-20250806FALSE000180822000018082202025-08-062025-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2025

GoHealth, Inc. (Exact name of registrant as specified in its charter)

Delaware001-3939085-0563805 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

222 W Merchandise Mart Plaza, Suite 175060654 Chicago,Illinois (Address of principal executive offices)(Zip Code)

(312) 386-8200 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock, $0.0001 par value per shareGOCOThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry Into a Material Definitive Agreement.

On August 6, 2025 (the “Closing Date”), GoHealth, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries, including Norvax, LLC, a Delaware limited liability company, as borrower (the “Borrower”), and Blizzard Midco, LLC, a Delaware limited liability company (“Holdings”), effected the transactions and entered into the agreements described in this Current Report on Form 8-K to enhance the Company’s financial flexibility.

Super Priority Term Loan Credit Agreement

On the Closing Date, the Borrower entered into a Superpriority Senior Secured Credit Agreement (the “Priming Credit Agreement”), with Holdings, the lenders party thereto, and Blue Torch Finance, LLC, as administrative agent and as collateral agent.

The Priming Credit Agreement governs a senior secured super priority term loan facility in an aggregate principal amount of $115.0 million (the “Priming Facility”) consisting of (a) $80.0 million in new-money term loans (the “Priming New Money Term Loans”), of which (i) $40.0 million were funded on the Closing Date and (ii) $40.0 million are available as delayed-draw term loans, and (b) $35.0 million of roll-up term loans (the “Priming Roll-Up Term Loans” and together with the “Priming New Money Term Loans,” the “Priming Term Loans”) resulting from the cashless conversion of a corresponding amount of existing Class A revolving loans at par that were outstanding under the Existing Credit Agreement (as defined below) into term loans on a dollar-for-dollar basis. Provided that no default or event of default has occurred and is continuing, delayed-draw term loans will be available to the Borrower on or after October 1, 2025, with the aggregate principal amount of such loans funded prior to November 1, 2025 not to exceed $15.0 million and prior to December 1, 2025, not to exceed $30.0 million, with the full amount available thereafter.

The proceeds of the Priming Term Loans can be used for working capital and other general corporate purposes and to pay transaction fees and expenses.

On the Closing Date, the lenders providing Priming New Money Term Loans received a closing fee equal to 3.00% of the Priming New Money Term Loans that was paid-in-kind by increasing the principal amount of outstanding Priming New Money Term Loans.

Maturity; Interest; MOIC Amount

The Priming Term Loans mature on August 5, 2029. The Priming New Money Term Loans bear interest in cash, at the Borrower’s election from time to time, at either (a) Term SOFR plus 5.50% per annum (subject to a 3.00% SOFR floor) or (b) Alternate Base Rate plus 4.50% (subject to a 4.00% Alternate Base Rate floor). Additionally, the Priming New Money Term Loans are also subject to a 2.00x multiple-on-invested-capital (“MOIC”), payable in cash upon partial or full repayment, prepayment, maturity

goco-20250513FALSE000180822000018082202025-05-132025-05-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025

GoHealth, Inc. (Exact name of registrant as specified in its charter)

Delaware001-3939085-0563805 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

222 W Merchandise Mart Plaza Suite 175060654 Chicago,Illinois (Address of principal executive offices)(Zip Code)

(312) 386-8200 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock, $0.0001 par value per shareGOCOThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.    Results of Operations and Financial Condition. On May 13, 2025, GoHealth, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits. (d)    Exhibits

Exhibit NumberExhibit Description 99.1Press release, dated May 13, 2025

104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GoHealth, Inc. (Registrant)

Date:May 13, 2025By:/s/ Brendan Shanahan Brendan Shanahan Chief Financial Officer (Principal Financial and Accounting Officer)